Quality Agreement

A Quality Agreement is a written, signed document distinct from the commercial supply agreement, allocating responsibilities for every Good Manufacturing Practice activity between a brand-owner (own-label distributor) and a contract manufacturer (CMO). The FDA's 2016 Contract Manufacturing Arrangements for Drugs: Quality Agreements guidance — though pharmaceutical in origin — is consistently cited in dietary supplement enforcement contexts and reflects the expected structure for supplement brand-owner / CMO relationships.

The Quality Agreement covers (1) responsibility allocation across the GMP control set — facilities and equipment, materials management, production, laboratory controls, packaging and labelling, batch records, quality unit roles, change control, deviation and OOS handling, complaints, recalls, returns, retention samples, stability, validation, regulatory inspections; (2) communication — notification triggers for deviations, OOS results, customer complaints, regulatory inspections, supplier or equipment changes, formula and label artwork changes; (3) audit rights — the brand-owner's right to audit the CMO facility, scope, frequency and response timelines; (4) term, termination and the transition of records and reserve samples on termination. Supplement-specific allocations add 21 CFR 111 elements: who runs identity testing of components, who runs finished-product testing, who owns the master manufacturing record, who approves label artwork.

The foundational principle, repeatedly affirmed in FDA Warning Letters to brand-owners whose CMOs caused the violation, is that 21 CFR 111 applies to the brand-owner as the own-label distributor as well as to the CMO. The contract reassigns activities; it does not reassign liability. A Quality Agreement that lives in a binder while the brand-owner's quality unit accepts everything the CMO ships without review is the brand-owner that finds out about contamination or label violations from a customer complaint, a competitor lab test or an FDA Warning Letter. NSF/ANSI 455-1 formalises the brand-owner counterpart to 455-2's manufacturer focus, codifying the qualification programme, the Quality Agreement and the batch record review and release process. In V5 the Quality Agreement allocations are live operating responsibilities — every GMP activity has a responsible party, every notification trigger has automatic routing, every audit and review has a schedule.